Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo.
Author(s) -
Ettore Porreca,
S Ucchino,
Concetta Di Febbo,
Nicola Bartolomeo,
Domenico Angelucci,
Antonio Napolitano,
Andrea Mezzetti,
Franco Cuccurullo
Publication year - 1994
Publication title -
arteriosclerosis and thrombosis a journal of vascular biology
Language(s) - English
Resource type - Journals
eISSN - 2330-9199
pISSN - 1049-8834
DOI - 10.1161/01.atv.14.2.299
Subject(s) - vascular smooth muscle , bromodeoxyuridine , in vivo , in vitro , deferoxamine , cell growth , dna synthesis , blood vessel , biology , thymidine , endocrinology , pharmacology , medicine , chemistry , biochemistry , smooth muscle , microbiology and biotechnology
Vascular smooth muscle cell (VSMC) growth is a primary component of accelerated and spontaneous atherosclerosis. Previous studies have shown that iron may be involved in the control of enzymatic activities that modulate DNA synthesis in human cells. In this study the effects of the iron chelator desferrioxamine on in vitro and in vivo VSMC proliferation were tested. Rat VSMCs in culture and a rabbit model of carotid artery balloon injury were used. Desferrioxamine showed a significant inhibitory effect on [3H]thymidine incorporation in cell cultures that was antagonized by iron supplementation. Desferrioxamine also provided effective preventive myointimal VSMC proliferation as assessed by bromodeoxyuridine labeling and morphometric analysis of endoluminal stenosis. These experiments suggested that iron may be involved in the control of VSMC proliferation and that desferrioxamine may have a role in preventing VSMC growth and myointimal proliferative lesions.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom